October 20, 2020: AstraZeneca will present 84 abstracts, including 12 oral presentations and three late-breaking abstracts, across its industry-leading renal portfolio which includes roxadustat, Farxiga (dapagliflozin) and Lokelma (sodium zirconium cyclosilicate), at ASN Kidney Week 2020 Reimagined, taking place virtually from 22-25 October 2020.
The data advance AstraZeneca’s ambition to create a coordinated pathway for renal patients to advance earlier diagnosis and help prevent or slow the progression of chronic kidney disease (CKD) and address its life-threatening complications, such as anaemia and hyperkalaemia.1,2
Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, said: “The breadth of data being presented by AstraZeneca demonstrates the growing momentum of our renal portfolio. Our ambition is to provide new treatments for hundreds of millions of patients with chronic kidney disease, a progressive condition for which there currently is no cure.
We are particularly excited to share insights into the safety and efficacy of roxadustat in anaemia of chronic kidney disease and new subgroup data from the DAPA-CKD trial looking at the benefit of Farxiga regardless of disease cause.”
Roxadustat – redefining the management of anaemia of CKD
More than 40 abstracts will be presented on roxadustat, a first-in-class oral hypoxia-inducible-factor prolyl hydroxylase inhibitor (HIF-PHI).
The abstracts provide new insights on the potential of the medicine to transform the standard of care in anaemia of CKD across key patient sub-populations, notably:
- Late-breaking presentations of pooled analyses of Phase III trialsinvestigating the association between haemoglobin levels and CV outcomes in dialysis-dependent (DD) and non-dialysis dependent (NDD)-CKD patients.
Cardiovascular (CV) outcomes are common and serious complications in patients with CKD. - An oral presentation exploring whether roxadustat can reduce the risk of hospitalisation for heart failure, a common comorbidity in patients with CKD.
- Analyses of whether roxadustat has the potential to reduce the risk of red blood cell (RBC) transfusions, a treatment for anaemia associated with additional complications, in both DD-CKD and NDD-CKD patients.
- An analysis exploring the effect of roxadustat on achieving haemoglobin levels ≥10 g/dL in patients with NDD-CKD.
- New data from pooled analyses of Phase III trials on DD-CKD patient subgroups, including those who are receiving peritoneal dialysis and are new to dialysis.
Farxiga – setting a new standard in early CKD protection
New late-breaking subgroup data from the ground-breaking DAPA-CKD Phase III trial evaluating the potential benefit of Farxiga in patients with CKD irrespective of the underlying cause.
Detailed results presented in August and published in The New England Journal of Medicine established Farxiga as the first medicine to significantly prolong survival in a renal outcomes trial in patients with CKD with and without type-2 diabetes (T2D).
Lokelma – advancing proactive potassium management
New sub-analyses of the DIALIZE Phase IIIb trial and real-world evidence in patients living with CKD and hyperkalaemia demonstrate the potential of Lokelma as an option for hyperkalaemia management.
Hyperkalaemia is a common complication in patients with CKD and can result in serious arrhythmias, sudden cardiac arrest, paralysis and weakness, and even death.
If not managed effectively, complications like hyperkalaemia can impact ongoing treatment approaches, leading to life-saving treatments being reduced or discontinued.
Uncovering the unique unmet needs of the CKD patient community
AstraZeneca will also present new insights into patients’ experiences living with CKD as well as actionable gaps in treatment and management.
New data will be presented from DISCOVER-CKD, a trial that assesses current real-world practice patterns and clinical management of patients with CKD.
It reveals the burden of disease and factors that determine poor clinical outcomes, underscoring the need for improved treatment options.”
